🇺🇸 FDA
Patent

US 12012455

Human monoclonal antibodies specific for FLT3 and uses thereof

granted A61KA61K2039/505A61K47/6849

Quick answer

US patent 12012455 (Human monoclonal antibodies specific for FLT3 and uses thereof) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Jun 13 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Jun 18 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 13 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61K, A61K2039/505, A61K47/6849, A61K47/6929, A61P